Sunday 22 December 2024
Internal Reference Number: FOI_7875
Date Request Received: 09/04/2024 00:00:00
Date Request Replied To: 30/04/2024 00:00:00
This response was sent via: By Email
Request Summary: The treatment of Haemophilia A
Request Category: Researcher
| Question Number 1: How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. | |
| Answer To Question 1: Mild: 21 patients Moderate <5 patients Severe <5 patients | |
| Question Number 2: In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products | |
| Answer To Question 2: • Advate <5 patients • Adynovi 0 patients • Elocta <5 patients. • Esperoct 0 patients • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 patients • Hemlibra (standalone) 0 patients • Hemlibra in combination with any Factor VIII 0 patients • NovoEight 0 patients • NovoSeven RT 0 patients • Nuwiq 0 patients • Obizur 0 patients • Refacto AF 0 patients • Any other products 0 patients | |
| Question Number 3: For patients treated with Advate in the last three months, please provide: • the number of haemophilia A patients treated prophylactically • the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) | |
| Answer To Question 3: • the number of haemophilia A patients treated prophylactically - 0 patients • the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) <5 patients | |
| Question Number 4: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products | |
| Answer To Question 4: • Advate 0 Patients • Adynovi 0 Patients • Elocta >5 patients • Esperoct 0 Patients • Factor Eight Inhibitor Bypass Activity (FEIBA) 0 Patients • Hemlibra (standalone) 0 Patients • Hemlibra in combination with any Factor VIII 0 Patients • NovoEight 0 Patients • NovoSeven RT 0 Patients • Nuwiq 0 Patients • Obizur 0 Patients • Refacto AF 0 Patients • Any other products 0 Patients | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
